NEW YORK (GenomeWeb News) – Indiana University has licensed a breast cancer biomarker that researchers at the school have discovered to Clarient for development as a pharmacogenomic assay, the school said today.

According to IU, patients who test positive for the biomarker — FOXA1 — are more likely to respond to anti-estrogen hormone therapies, such as tamoxifen. The university said that in two studies involving around 675 patients, those who tested positive for the presence of FOXA1 had cancer considered less aggressive.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

By sequencing two ancient dog genomes, researchers from the US and Germany suggest that dogs were domesticated in a single event, the Washington Post reports.

In Genome Research this week: population dynamics of E. coli infection, lncRNA expression changes in macaque aging, and more.

Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.